Kevin Van der Jeught
Kevin Van der Jeught
Dirección de correo verificada de iu.edu
TítuloCitado porAño
Targeting the tumor microenvironment to enhance antitumor immune responses
K Van der Jeught, L Bialkowski, L Daszkiewicz, K Broos, C Goyvaerts, ...
Oncotarget 6 (3), 1359, 2015
442015
A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice
T Liechtenstein, N Perez-Janices, M Gato, F Caliendo, G Kochan, ...
Oncotarget 5 (17), 7843, 2014
382014
Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity
K Van der Jeught, PT Joe, L Bialkowski, C Heirman, L Daszkiewicz, ...
Oncotarget 5 (20), 10100, 2014
332014
Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells
S Van Lint, D Renmans, K Broos, L Goethals, S Maenhout, D Benteyn, ...
Cancer immunology research 4 (2), 146-156, 2016
282016
Particle-mediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of type I interferon
K Broos, K Van der Jeught, J Puttemans, C Goyvaerts, C Heirman, ...
Molecular Therapy-Nucleic Acids 5, e326, 2016
262016
Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours
L Bialkowski, A Van Weijnen, K Van der Jeught, D Renmans, ...
Scientific reports 6, 22509, 2016
152016
Drug resistance and new therapies in colorectal cancer
K Van der Jeught, HC Xu, YJ Li, XB Lu, G Ji
World journal of gastroenterology 24 (34), 3834, 2018
102018
Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of Non-Hodgkin Lymphoma
A Krasniqi, M D'Huyvetter, C Xavier, K Van der Jeught, S Muyldermans, ...
Molecular cancer therapeutics 16 (12), 2828-2839, 2017
82017
Pharmacokinetics of radiolabeled dimeric sdAbs constructs targeting human CD20
A Krasniqi, M Bialkowska, C Xavier, K Van der Jeught, S Muyldermans, ...
New biotechnology 45, 69-79, 2018
52018
Immune checkpoint blockade combined with IL‐6 and TGF‐β inhibition improves the therapeutic outcome of m RNA‐based immunotherapy
L Bialkowski, K Van der Jeught, S Bevers, P Tjok Joe, D Renmans, ...
International journal of cancer 143 (3), 686-698, 2018
52018
Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer
Y Liu, H Xu, K Van der Jeught, Y Li, S Liu, L Zhang, Y Fang, X Zhang, ...
Journal of Clinical Investigation 128 (7), 2951-2965, 2018
52018
Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy
K Van der Jeught, S Van Lint, K Thielemans, K Breckpot
Oncoimmunology 4 (5), e1005504, 2015
52015
Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II
Y Li, Y Liu, H Xu, G Jiang, K Van der Jeught, Y Fang, Z Zhou, L Zhang, ...
Nature communications 9 (1), 4394, 2018
32018
Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
Y Liu, J Xu, HH Choi, C Han, Y Fang, Y Li, K Van der Jeught, H Xu, ...
Nature communications 9 (1), 4718, 2018
22018
Adjuvant-Enhanced mRNA Vaccines
L Bialkowski, K Van der Jeught, D Renmans, A van Weijnen, C Heirman, ...
RNA Vaccines, 179-191, 2017
22017
Dendritic Cell Targeting mRNA Lipopolyplexes Combine Strong Antitumor T-Cell Immunity with Improved Inflammatory Safety
K Van Der Jeught, S De Koker, L Bialkowski, C Heirman, P Tjok Joe, ...
ACS nano 12 (10), 9815-9829, 2018
12018
Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer
J Xu, Y Liu, Y Li, H Wang, S Stewart, K Van der Jeught, P Agarwal, ...
Nature nanotechnology 14 (4), 388, 2019
2019
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–17